<DOC>
	<DOCNO>NCT00547261</DOCNO>
	<brief_summary>The purpose study determine maximally tolerate dose dose limit toxicity antimitotic , tubulin bind investigational drug patient fail standard anticancer treatment .</brief_summary>
	<brief_title>Phase I Dose Finding Study SSR97225 Given Patients With Refractory Cancer</brief_title>
	<detailed_description />
	<criteria>Diagnosis metastatic locally advanced nonhematological cancer Patients solid tumor refractory therapy therapy exist Five prior chemotherapy line metastatic disease Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 Patients discontinue previous specific anticancer treatment Patients recover toxic effect previous specific anticancer treatment ( exclude alopecia ) Patients abnormal biological/hematological parameter , cardiac abnormality serious infection/intercurrent illness likely jeopardize patient 's safety course protocol treatment No adequate birth control methods The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>antimitotic</keyword>
	<keyword>tubulin binder</keyword>
</DOC>